News · 26 weeks111+5%
2025-12-142026-06-07
Mix5590d
- SEC Filings29(53%)
- Other21(38%)
- Insider3(5%)
- Earnings1(2%)
- M&A1(2%)
Latest news
25 items- PRNYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE HistoryNYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, June 5, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on June 5thInvestors are reacting to the May jobs report after the DOW climbed to a record close on Thursday.AstraZeneca (NYSE:AZN) is celebrating its February transfer to the NYSE, the largest transfer by market capitalization in the NYSE's 234-year history.NYSE Live will provide exclusive coverage of CEO Pascal Soriot's remarks
- PRCamizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 TrialSwitching to camizestrant led to a 99% median reduction in total ctDNA vs. a 64% increase for patients who remained on standard of care 51% of patients receiving the camizestrant combination achieved total ctDNA clearance vs. 1.9% with standard of care – early total ctDNA clearance was associated with an improvement in long-term outcome Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintained its progression-free survival (PFS) benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second pr
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRIMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trialPositive overall survival trend in favor of STRIDE regimen with lenvatinib and TACE Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE), demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization. Patients in the investigational arms were treated with the STRIDE regimen (Single Tremelimumab-actl Regular Interval Durvalumab), with or without lenvatinib, prior to TACE and then in combinati
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRIMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancerBased on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of IMFINZI added to BCG vs. BCG alone AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval by the Food and Drug Administration (FDA) is based on positive results from the POTOMAC Phase III trial which were presented at the European Society for Medical Oncology (ESMO) Congress 2025 and simultaneously published in The Lancet. I
- SECSEC Form 25-NSE filed by AstraZeneca PLC25-NSE - ASTRAZENECA PLC (0000901832) (Subject)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- INSIDEROfficer Sharma Mani sold $2,209,482 worth of Ordinary Shares (11,893 units at $185.78), decreasing direct ownership by 38% to 19,262 units (SEC Form 4)4 - ASTRAZENECA PLC (0000901832) (Issuer)
- PRDATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidatesAstraZeneca and Daiichi Sankyo's DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 Phase III trial DATROWAY has the potential to become the new standard of care in this setting May 22, 2026 — AstraZeneca and Daiichi Sankyo's DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval follows Priority Review by the Food and Drug Admin
- PRDatroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor CandidatesDaiichi Sankyo and AstraZeneca's Datroway is the only TROP2 directed antibody drug conjugate to prolong overall survival in this setting versus chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 phase 3 trial Datroway has the potential to become the new standard of care in this setting Daiichi Sankyo (TSE: 4568) and AstraZeneca's (NYSE:AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 direc
- PREnhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid TumorsEnhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (NYSE:AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with H
- PRAstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) in early liver cancer Phase III data from SERENA-6, DESTINY-Breast09 and TROPION-Breast02 span all three major subtypes of metastatic breast cancer CARES Phase III results will demonstrate highly clinically meaningful benefit of anti-fibril therapy, anselamimab, for kappa light chain amyloidosis AstraZeneca advances its ambition to eliminate cancer as a cause of death and transform outcomes for people living with rare diseases with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRBAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertensionApproval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension BAXFENDY 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline in BaxHTN trial AstraZeneca's BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled. This press release features multimedia. View the full release here: https://www.businesswire.com/news
- PRENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancerApproved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial Two new indications bring AstraZeneca and Daiichi Sankyo's ENHERTU into curative-intent setting, reinforcing its role across stages of HER2-positive breast cancer AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively. In the neoadjuvant setting, ENHERTU followe
- PREnhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast CancerApproved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3 trial Two new indications bring Daiichi Sankyo and AstraZeneca's Enhertu into curative-intent setting, reinforcing its role across stages of HER2 positive breast cancer Enhertu now approved for nine indications with six across both early and metastatic HER2 positive breast cancer Enhertu® (fam-trastuzumab deruxtecan-nxki) has been approved by the U.S. Food and Drug Administration (FDA) for two new breast cancer indications in the neoadjuvant and adjuvant settings of patients with HER2 positive early breast cancer. In the neoadjuvant setting, Enhertu foll
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRPerioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trialPerioperative IMFINZI plus IMJUDO® (tremelimumab-actl) and neoadjuvant EV showed a statistically significant and clinically meaningful improvement in event-free survival and a favorable trend for overall survival High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible for or had declined cisplatin-based chemotherapy. Pa
AZN FAQ
8 questionsWhat does AstraZeneca PLC do?
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir...Where does AZN stock trade?
AstraZeneca PLC (AZN) is listed on NYSE.What sector and industry is AZN in?
AstraZeneca PLC operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AstraZeneca PLC go public?
AstraZeneca PLC (AZN) completed its IPO in 2026.Does AZN pay a dividend?
AZN's most recent ex-dividend date was 2026-02-20 with a cash dividend of $2.17 per share. No future ex-date is on file yet.What are analysts saying about AZN?
AstraZeneca PLC has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-01-27.What companies are similar to AZN?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVS (Novartis AG), PFE (Pfizer Inc.), BMY (Bristol-Myers Squibb Company). Compare AZN side-by-side with any of them on Quantisnow.How can I track AZN on Quantisnow?
Quantisnow aggregates AstraZeneca PLC's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZN to receive live email and push alerts on every new disclosure.